Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Additional file 10)
306 Targeting immunometabolic adaptations is gaining traction
Reported Adverse Effects In the available case series and observational literature, the most commonly reported adverse effects include: Injection-site redness or mild induration in approximately 8 to 12% of users Transient nausea, most often associated with oral formulations or higher injectable doses Lightheadedness in a small number of patients shortly after injection (under 2% of reported cases) Vivid dreams or mild sleep changes, reported anecdotally by a subset of users with no clear mechanistic explanation No published human case reports as of July 2025 document serious organ toxicity, malignancy, or endocrine disruption attributable to BPC-157
Yes repeated injections into the same subcutaneous site cause lipohypertrophy (tissue thickening) or lipoatrophy (tissue thinning), which impairs absorption consistency and increases scar tissue formation
US$ 25.33
US$ 27.81
US$ 21.60
